# Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy

*PRI Rank #19 · Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026/rank-19*

| Field | Value |
| --- | --- |
| Rank | #19 |
| 18m citations | 40 |
| Journal | Blood |
| Year | 2024 |
| DOI | 10.1182/blood.2023019706 |
| Corresponding authors | Jiuyang Liu |
| Institution | BeiGene (Beijing) Co, Ltd, China |

**Ranking page:** [Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026](https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026)

**Paper link:** [10.1182/blood.2023019706](https://doi.org/10.1182/blood.2023019706)

## Topics

sonrotoclax · venetoclax · BCL-2 · G101V mutation · venetoclax resistance · BCL2 inhibitor · chronic lymphocytic leukemia · hematologic malignancy · apoptosis · Pro-apoptotic proteins · P2 pocket · Crystal structure · Drug resistance · BCL2 variants · binding mode · tumor growth inhibition · second-generation inhibitor

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026. https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026. Accessed 2026-10-28.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```